ArticleCureus2026
Efficacy of a Standardized Ginger Extract for Menstrual Pain and Associated Symptoms in Women With Primary Dysmenorrhea: A Randomized, Double-Blind, Placebo-Controlled Trial.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary dysmenorrhea, a common gynecological condition characterized by painful menstrual cramps, significantly impairs quality of life. Ginger has traditionally been used for pain relief and is proposed to exert anti-inflammatory and analgesic effects. This study aimed to evaluate the efficacy and safety of a standardized ginger extract compared with placebo in women with primary dysmenorrhea.
methodsIn this randomized, double-blind, placebo-controlled, multicenter clinical study, participants with primary dysmenorrhea received either a standardized ginger extract or placebo twice daily for 90 days. The primary endpoints were changes in pain severity, assessed using the Visual Analog Scale (VAS), and dysmenorrhea severity, assessed using the Working Ability, Location, Intensity, Days of Pain, Dysmenorrhea (WaLIDD) score. Secondary endpoints included changes in menstrual symptom burden, assessed using the Menstrual Distress Questionnaire (MEDI-Q), menstrual fluid flow, and global assessments. Exploratory endpoints included prostaglandin F2α (PGF2α) levels. Efficacy analyses were performed in the intention-to-treat (ITT) and per-protocol (PP) populations.
resultsCompared with placebo (n = 47), standardized ginger extract (n = 49) significantly reduced pain severity and overall dysmenorrhea severity from Cycle 1 onward. At Cycle 3, VAS and WaLIDD scores were reduced by 31.2%-33.3% and 62.4%-63.5%, respectively, from baseline (p < 0.001). Significant improvements in menstrual symptom burden and menstrual fluid flow (31.9% reduction) were observed compared with placebo (p < 0.05 to p < 0.001). PGF2α levels decreased significantly by 11.6%-11.9% in the ginger extract group, whereas they increased in the placebo group (p < 0.001). The intervention was well tolerated, with no clinically significant adverse events reported.
conclusionStandardized ginger extract significantly reduced pain severity, dysmenorrhea severity, menstrual symptom burden, and menstrual fluid flow in women with primary dysmenorrhea. Its favorable safety and tolerability profile support its potential utility as a non-hormonal therapeutic approach for the management of primary dysmenorrhea.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.